Acute Psychotropic Effects of Oral Cannabis Extract with a Defined Content of Δ9-Tetrahydrocannabinol (THC) in Healthy Volunteers
R. M. Kaufmann1
, B. Kraft2
, R. Frey1
, D. Winkler1
, S. Weiszenbichler1
, C. Bäcker1
, S. Kasper1
, H. G. Kress2
1Division of Biological Psychiatry, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
2Division of Special Anesthesia and Pain Therapy, Department of Anesthesia, General Intensive Care and Pain Control, Medical University of Vienna, Vienna, Austria
Introduction: The medical use of cannabinoids is limited mainly by their undesirable effects. With respect to acute psychotropic effects, the aim of this study is the comparison of an oral cannabis extract and low-dose diazepam in a cross-over experiment in drug-naïve healthy women.
Methods: Sixteen healthy females participated in this randomized, double-blind, active comparator-controlled, single-dose, balanced 2-way cross-over study. Cannabis extract with standardised Δ9-tetrahydrocannabinol (THC) content (20 mg) or active placebo (5 mg diazepam) was administered orally. Subjects were assessed by self- and observer-rated visual analogue scales (VAS), the brief psychiatric rating scale (BPRS) and three psychomotor tests up to 6 h after administration.
Results: VAS showed significantly elevated fatigue, drowsiness, dizziness, and “feeling high” after cannabis as compared to baseline and diazepam. BPRS scores were significantly higher after cannabis intake. Only in one psychomotor test a decrease of psychomotor activity after cannabis was evident. One subject in the cannabis condition experienced severe transient psychotic symptoms.
Discussion: Orally administered cannabis produced significant central depressant side-effects compared to diazepam, mostly subjective effects (VAS) but marginal effects in psychomotor performance in 15 healthy females. Regarding the medical use of cannabis, a rigorous benefit-risk analysis and an exact psychiatric assessment before and during treatment are necessary.
References
1
Adams IB, Martin BR.
Cannabis: pharmacology and toxicology in animals and humans.
Addiction.
1996;
91
1585-1614
4
Baigent M, Holme G, Hafner RJ.
Self reports of the interaction between substance abuse and schizophrenia.
Aust N Zealand J Psychiatry.
1995;
29
69-74
6
Bird KD, Boleyn T, Chesher GB. et al .
Intercannabinoid and cannabinoid-ethanol interactions and their effects on human performance.
Psychopharmacology.
1980;
71
181-188
7
Block RI, Erwin WJ, Farinpour R. et al .
Sedative, stimulant, and other subjective effects of marijuana: relationships to smoking techniques.
Pharmacol Biochem Behav.
1998;
59
405-412
9
Borland RG, Nicholson AN.
Immediate effects on human performance of a 1,5-benzodiazepine (clobazam) compared with the 1,4-benzodiazepines, chlordiazepoxide hydrochloride and diazepam.
Br J Clin Pharmacol.
1975;
2
215-221
10
Campell FA, Tramer MR, Carroll D. et al .
Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.
BMJ.
2001;
323
13-16
12 Chait LD, Pierri J. Effects of smoked marijuana on human performance: a critical review. In: Murphy LL, Bartke A (eds.) Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Boca Raton, CRC Press 1992: 387-423
16
Curran HV, Brignell C, Fletcher S. et al .
Cognitive and subjective dose-response effects of acute oral Δ9-tetrahydrocannabinol (THC) in infrequent cannabis users.
Psychopharmacology.
2002;
164
61-70
17
Devane WA, Dysarz FA, Johnson MR. et al .
Determination and characteristics of a cannabinoid receptor in rat brain.
Mol Pharmacology.
1988;
34
605-613
18
Devane WA, Hanus L, Breuer A. et al .
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Science.
1992;
258
1946-1949
19
D’Souza DC, Perry E, MacDougall L. et al .
The pychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.
Neuropsychopharmacology.
29;
2004
1558-1572
22
Favrat B, Menetrey A, Augsburger M. et al .
Two cases of “cannabis acute psychosis” following the administration of oral cannabis.
BMC Psychiatry.
2005;
5
17-22
23
Frey R, Decker K, Reinfried L. et al .
Effect of rest on physicians` performance in an emergency department, objectified by electroencephalographic analyses and psychometric tests.
Crit Care Med.
2002;
30
2322-2329
29 Grünberger J. [Psychodiagnostik des Alkoholkranken. Methodischer Beitrag zur Bestimmung der Organizität in der Psychiatrie. Article in German]. Maudrich, Wien, Austria 1977
30
Grünberger J, Linzmayer L, Dietzl M. et al .
The effect of biologically-active light on the noo- and thymopsyche and on psychophysiological variables in healthy volunteers.
Int J Psychophysiol.
1993;
15
27-37
33
Hambrecht M, Häfner H.
Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective.
Aust NZ J Psychiatry.
2000;
34
468-475
36
Holdcroft A, Maze M, Dore C. et al .
A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management.
Anesthesiology.
2006;
104
1040-1046
40
Kalant H.
Adverse effects of cannabis on health: an update of the literature since 1996.
Prog Neuropsychopharmacol Biol Psychiatry.
2004;
28
849-863
42
Kopelowicz A, Vendura J, Libermann RP. et al .
Consistency of brief psychiatric rating scale factor structure across a broad spectrum of schizophrenia patients.
Psychopathology.
2007;
41
77-84
43
Kraft B, Frickey NA, Kaufmann RM. et al .
Lack Of Analgesia By Oral Standardized Cannabis Extract On Acute Inflammatory Pain And Hyperalgesia In Volunteers.
Anesthesiology.
2008;
109
101-110
46
Linzmayer L, Arnold O, Saletu-Zylarz GM. et al .
Daytime noopsychic and thymopsychic dysfunctions in nonorganic insomnia related to different mental disorders.
Somnologie.
2002;
6
141-148
48
Mason OJ, Morgan CJM, Stefanovic A. et al .
The psychotomimetic states inventory (PSI): Measuring psychotic-type experiences from ketamine and cannabis.
Schizophrenia Res.
2008;
103
138-142
49
Mattila MJ, Vanakoski J, Kalska H. et al .
Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory.
Pharmacol Biochem Behav.
1998;
59
917-923
52
Moore THM, Zammit S, Lingford-Hughes A. et al .
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Lancet.
2007;
370
319-328
54
Nicholson AN, Turner C, Stone BM. et al .
Effect of Δ9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults.
J Clin Psychopharmacology.
2004;
24
305-313
56
Overall JE, Gorham DR.
The brief psychiatric rating scale (BPRS): Recent developments in ascertainment and scaling.
Psychopharmac Bull.
1988;
24
97-99
58
Peters BA, Lewis EG, Dustman RE. et al .
Sensory, perceptual, motor and cognitive functioning and subjective reports following oral administration of Δ9-tetrahydrocannabinol.
Psychopharmacology.
1976;
47
141-148
60
Ramaekers J, Kauert G, Theunissen E. et al .
Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users.
J Psychopharmacol.
2009;
23
266-277
63
Sheehan DV, Lecrubier Y, Sheehan KH. et al .
The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.
J Clin Psychiatry.
1998;
59
((Suppl 20))
22-33
72
Zajicek J, Fox P, Sanders H. et al .
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.
Lancet.
2003;
362
1517-1526